BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Gupta A, Gonzalez-Rojas Y, Juarez E, Crespo Casal M, Moya J, Rodrigues Falci D, Sarkis E, Solis J, Zheng H, Scott N, Cathcart AL, Parra S, Sager JE, Austin D, Peppercorn A, Alexander E, Yeh WW, Brinson C, Aldinger M, Shapiro AE; COMET-ICE Investigators. Effect of Sotrovimab on Hospitalization or Death Among High-risk Patients With Mild to Moderate COVID-19: A Randomized Clinical Trial. JAMA 2022;327:1236-46. [PMID: 35285853 DOI: 10.1001/jama.2022.2832] [Cited by in Crossref: 47] [Cited by in F6Publishing: 62] [Article Influence: 47.0] [Reference Citation Analysis]
Number Citing Articles
1 Caskey M, Kuritzkes DR. Monoclonal Antibodies as Long-Acting Products: What Are We Learning From Human Immunodeficiency Virus (HIV) and Coronavirus Disease 2019 (COVID-19)? Clinical Infectious Diseases 2022;75:S530-S540. [DOI: 10.1093/cid/ciac751] [Reference Citation Analysis]
2 Zheng B, Green ACA, Tazare J, Curtis HJ, Fisher L, Nab L, Schultze A, Mahalingasivam V, Parker EPK, Hulme WJ, Bacon SCJ, Devito NJ, Bates C, Evans D, Inglesby P, Drysdale H, Davy S, Cockburn J, Morton CE, Hickman G, Ward T, Smith RM, Parry J, Hester F, Harper S, Mehrkar A, Eggo RM, Walker AJ, Evans SJW, Douglas IJ, Mackenna B, Goldacre B, Tomlinson LA. Comparative effectiveness of sotrovimab and molnupiravir for prevention of severe covid-19 outcomes in patients in the community: observational cohort study with the OpenSAFELY platform. BMJ 2022. [DOI: 10.1136/bmj-2022-071932] [Reference Citation Analysis]
3 Bajema KL, Wang XQ, Hynes DM, Rowneki M, Hickok A, Cunningham F, Bohnert A, Boyko EJ, Iwashyna TJ, Maciejewski ML, Viglianti EM, Streja E, Yan L, Aslan M, Huang GD, Ioannou GN. Early Adoption of Anti–SARS-CoV-2 Pharmacotherapies Among US Veterans With Mild to Moderate COVID-19, January and February 2022. JAMA Netw Open 2022;5:e2241434. [DOI: 10.1001/jamanetworkopen.2022.41434] [Reference Citation Analysis]
4 Takayama S, Namiki T, Arita R, Ono R, Kikuchi A, Ohsawa M, Saito N, Suzuki S, Nakae H, Kobayashi S, Yoshino T, Ishigami T, Tanaka K, Nochioka K, Takagi A, Mimura M, Yamaguchi T, Ishii T, Hisanaga A, Mitani K, Ito T. Multicenter, randomized controlled trial of traditional Japanese medicine, kakkonto with shosaikotokakikyosekko, for mild and moderate coronavirus disease patients. Front Pharmacol 2022;13. [DOI: 10.3389/fphar.2022.1008946] [Reference Citation Analysis]
5 Krekeler C, Reitnauer L, Bacher U, Khandanpour C, Steger L, Boeckel GR, Klosner J, Tepasse P, Kemper M, Hennies MT, Mesters R, Stelljes M, Schmitz N, Kerkhoff A, Schliemann C, Mikesch J, Schmidt N, Lenz G, Bleckmann A, Shumilov E. Efficacy of COVID-19 Booster Vaccines in Patients with Hematologic Malignancies: Experiences in a Real-World Scenario. Cancers 2022;14:5512. [DOI: 10.3390/cancers14225512] [Reference Citation Analysis]
6 Autmizguine J, Barton M, Burton C, Dixit D, Papenburg J, Robinson J, Top KA, Rubin E, for the AMMI Canada treatment of acute COVID-19 in pediatrics working group. AMMI Canada Practice Point on the treatment of acute COVID-19 in pediatrics. Official Journal of the Association of Medical Microbiology and Infectious Disease Canada 2022. [DOI: 10.3138/jammi-2022-09-20] [Reference Citation Analysis]
7 Harman K, Nash SG, Webster HH, Groves N, Hardstaff J, Bridgen J, Blomquist PB, Hope R, Ashano E, Myers R, Rokadiya S, Hopkins S, Brown CS, Chand M, Dabrera G, Thelwall S. Comparison of the risk of hospitalisation among BA.1 and BA.2 COVID-19 cases treated with Sotrovimab in the community in England.. [DOI: 10.1101/2022.10.21.22281171] [Reference Citation Analysis]
8 McMahon JH, Lau JSY, Coldham A, Roney J, Hagenauer M, Price S, Bryant M, Garlick J, Paterson A, Lee SJ, O'Bryan J, Hearps A, Tachedjian G, Pinskier H, Phillips C, Garrow S, Pinskier N, Melvin R, Blakeway L, Wisniewski JA, Byers S, Badoordeen GZ, Pereira S, Pragastis K, Trubiano JA, Chua KYL, Kainer M, Molton JS, Gardiner BJ, Pierce AB, Cheng A, Rogers BA, Peleg AY. Favipiravir in early symptomatic COVID-19, a randomised placebo-controlled trial. EClinicalMedicine 2022;54:101703. [PMID: 36284645 DOI: 10.1016/j.eclinm.2022.101703] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Yamakawa K, Yamamoto R, Terayama T, Hashimoto H, Ishihara T, Ishimaru G, Imura H, Okano H, Narita C, Mayumi T, Yasuda H, Yamada K, Yamada H, Kawasaki T, Shime N, Doi K, Egi M, Ogura H, Aihara M, Kushimoto S, Nishida O; Special Committee of the Japanese Clinical Practice Guidelines for the Management of Sepsis and Septic Shock 2020 (J‐SSCG 2020), the COVID‐19 Task Force. Japanese rapid/living recommendations on drug management for COVID-19: updated guidelines (July 2022). Acute Med Surg 2022;9:e789. [PMID: 36267628 DOI: 10.1002/ams2.789] [Reference Citation Analysis]
10 Murakami N, Hayden R, Hills T, Al-Samkari H, Casey J, Del Sorbo L, Lawler PR, Sise ME, Leaf DE. Therapeutic advances in COVID-19. Nat Rev Nephrol 2022. [PMID: 36253508 DOI: 10.1038/s41581-022-00642-4] [Reference Citation Analysis]
11 De la Fuente IM, Malaina I, Fedetz M, Chruszcz M, Grandes G, Targoni O, Lozano-pérez AA, Shteyer E, Ya’acov AB, de la Cámara AG, Borobia AM, Carrasco-pujante J, Pijoan JI, Bringas C, Pérez-yarza G, Ouro A, Crawford MJ, Shoshan-barmatz V, Zhurov V, López JI, Knafo S, Tary-lehmann M, Gabaldón T, Grbic M. Stability of SARS-CoV-2 spike antigens against mutations.. [DOI: 10.1101/2022.10.13.22280980] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Lammert A, Schnuelle P, Rabenau HF, Ciesek S, Krämer BK, Göttmann U, Drüschler F, Keller C, Rose D, Blume C, Thomas M, Kohmer N, Lammert A. SARS-CoV-2 Vaccination in Kidney Transplant Recipients—Stratified Analysis of the Humoral Immune Response. Transplantation Direct 2022;8:e1384. [DOI: 10.1097/txd.0000000000001384] [Reference Citation Analysis]
13 Ling KM, Dougan M. Monoclonal antibodies for the treatment of COVID-19 infection in children. Expert Rev Anti Infect Ther 2022. [PMID: 36225144 DOI: 10.1080/14787210.2022.2134117] [Reference Citation Analysis]
14 Amani B, Amani B. Efficacy and safety of sotrovimab in patients with COVID-19: A rapid review and meta-analysis. Rev Med Virol 2022;:e2402. [PMID: 36226323 DOI: 10.1002/rmv.2402] [Reference Citation Analysis]
15 Hentzien M, Owen A, Strub-wourgaft N, Pérez-casas C, Trøseid M, Calmy A. Rethinking treatment paradigms for the deployment of SARS-CoV-2 antiviral drugs on the shifting landscape of new variants. Front Microbiol 2022;13:998287. [DOI: 10.3389/fmicb.2022.998287] [Reference Citation Analysis]
16 Bahakel H, Murphy C, Frenck RW, Grimley MS, Marsh RA, Paulsen GC, Haslam DB, Phillips CL, Courter J, Spearman P, Schulert G, Danziger-isakov L. Single Site Experience of the use of Monoclonal Antibodies for the Treatment of COVID-19 in High-risk Pediatric and Young Adult Patients. Pediatric Infectious Disease Journal 2022;Publish Ahead of Print. [DOI: 10.1097/inf.0000000000003703] [Reference Citation Analysis]
17 Razonable RR, Tulledge-Scheitel SM, Hanson SN, Arndt RF, Speicher LL, Seville TA, Larsen JJ, Ganesh R, O'Horo JC. Real-world Clinical Outcomes of Bebtelovimab and Sotrovimab Treatment of High-risk Persons With Coronavirus Disease 2019 During the Omicron Epoch. Open Forum Infect Dis 2022;9:ofac411. [PMID: 36213724 DOI: 10.1093/ofid/ofac411] [Reference Citation Analysis]
18 Suzuki Y, Shibata Y, Minemura H, Nikaido T, Tanino Y, Fukuhara A, Kanno R, Saito H, Suzuki S, Inokoshi Y, Sando E, Sakuma H, Kobayashi T, Kume H, Kamimoto M, Aoki H, Takama A, Iizuka T, Kamiyama T, Nakayama M, Saito K, Tanigawa K, Sato M, Waragai Y, Kambe T, Kanzaki N, Azuma T, Okamoto H, Sakamoto K, Nakamura Y, Ohtani H, Waragai M, Maeda S, Ishida T, Sugino K, Abe W, Tsukada Y, Lee T, Yamada R, Sato R, Onuma T, Tomita H, Saito M, Watanabe N, Rikimaru M, Kawamata T, Morimoto J, Togawa R, Sato Y, Saito J, Kanazawa K, Hamaguchi S, Iseki K. Real-world clinical outcomes of treatment with molnupiravir for patients with mild- to-moderate coronavirus disease 2019 during the Omicron variant pandemic.. [DOI: 10.21203/rs.3.rs-2118653/v1] [Reference Citation Analysis]
19 White H, Mcdonald SJ, Barber B, Davis J, Burr L, Nair P, Mukherjee S, Tendal B, Elliott J, Mcgloughlin S, Turner T. Care for adults with COVID ‐19: living guidelines from the National COVID ‐19 Clinical Evidence Taskforce. Medical Journal of Australia 2022;217:368-378. [DOI: 10.5694/mja2.51718] [Reference Citation Analysis]
20 Prameswari HS, Putra ICS, Raffaello WM, Nathaniel M, Suhendro AS, Khalid AF, Pranata R. Managing Covid-19 in patients with heart failure: current status and future prospects. Expert Rev Cardiovasc Ther 2022. [PMID: 36185009 DOI: 10.1080/14779072.2022.2132230] [Reference Citation Analysis]
21 Gottlieb RL, Razonable RR. Stewardship of COVID-19 volunteers by nested trial design. The Lancet Infectious Diseases 2022;22:1400-1401. [DOI: 10.1016/s1473-3099(22)00429-7] [Reference Citation Analysis]
22 Pogue JM, Mccreary EK. Monoclonals for patients hospitalised with COVID-19. The Lancet Respiratory Medicine 2022;10:928-930. [DOI: 10.1016/s2213-2600(22)00222-3] [Reference Citation Analysis]
23 De Boeck I, Cauwenberghs E, Spacova I, Gehrmann T, Eilers T, Delanghe L, Wittouck S, Bron PA, Henkens T, Gamgami I, Simons A, Claes I, Mariën J, Ariën KK, Bakokimi D, Loens K, Jacobs K, Ieven M, Bruijning-Verhagen P, Delputte P, Coenen S, Verhoeven V, Lebeer S. Randomized, Double-Blind, Placebo-Controlled Trial of a Throat Spray with Selected Lactobacilli in COVID-19 Outpatients. Microbiol Spectr 2022;:e0168222. [PMID: 36154666 DOI: 10.1128/spectrum.01682-22] [Reference Citation Analysis]
24 Cheng MM, Reyes C, Satram S, Birch H, Gibbons DC, Drysdale M, Bell CF, Suyundikov A, Ding X, Maher MC, Yeh W, Telenti A, Corey L. Real-world Effectiveness of Sotrovimab for the Early Treatment of COVID-19 During SARS-CoV-2 Delta and Omicron Waves in the United States.. [DOI: 10.1101/2022.09.07.22279497] [Reference Citation Analysis]
25 Kneidinger N, Hecker M, Bessa V, Hettich I, Wald A, Wege S, Nolde AB, Oldigs M, Syunyaeva Z, Wilkens H, Gottlieb J. Outcome of lung transplant recipients infected with SARS-CoV-2/Omicron/B.1.1.529: a Nationwide German study. Infection 2022. [PMID: 36083405 DOI: 10.1007/s15010-022-01914-8] [Reference Citation Analysis]
26 Blann AD, Heitmar R. SARS-CoV-2 and COVID-19: A Narrative Review. Br J Biomed Sci 2022;79:10426. [DOI: 10.3389/bjbs.2022.10426] [Reference Citation Analysis]
27 Nepali K, Sharma R, Sharma S, Thakur A, Liou JP. Beyond the vaccines: a glance at the small molecule and peptide-based anti-COVID19 arsenal. J Biomed Sci 2022;29:65. [PMID: 36064696 DOI: 10.1186/s12929-022-00847-6] [Reference Citation Analysis]
28 Kobbe R, Schulze-Sturm U, Kurnaz P, Rau C, Tallarek AC, Lütgehetmann M, Jordan S, Schmiedel S. Vertical anti-SARS-CoV-2 monoclonal antibody transfer from mothers to HIV-exposed and unexposed infants. AIDS 2022;36:1613-5. [PMID: 35979836 DOI: 10.1097/QAD.0000000000003306] [Reference Citation Analysis]
29 Zaqout A, Almaslamani MA, Chemaitelly H, Hashim SA, Ittaman A, Alimam A, Rustom F, Daghfal J, Abukhattab M, Almukdad S, Kaleeckal AH, Latif AN, Butt AA, Bertollini R, Al-khal A, Omrani AS, Abu-raddad LJ. Effectiveness of the neutralizing antibody sotrovimab among high-risk patients with mild to moderate SARS-CoV-2 in Qatar. International Journal of Infectious Diseases 2022. [DOI: 10.1016/j.ijid.2022.09.023] [Reference Citation Analysis]
30 Mohamed Y, El-maradny YA, Saleh AK, Nayl AA, El-gendi H, El-fakharany EM. A comprehensive insight into current control of COVID-19: Immunogenicity, vaccination, and treatment. Biomedicine & Pharmacotherapy 2022;153:113499. [DOI: 10.1016/j.biopha.2022.113499] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
31 Duclaux-loras R, Belot A. Les biothérapies en pédiatrie. Perfectionnement en Pédiatrie 2022;5:193-201. [DOI: 10.1016/j.perped.2022.07.035] [Reference Citation Analysis]
32 Amaral RG, Santana RRR, Barbosa BO, Araújo YB, Lauton Santos S, Andrade LN. The The use of corticosteroid therapy for COVID-19 patients: an evidence-based overview. Rev Cienc Saude 2022;12:4-11. [DOI: 10.21876/rcshci.v12i3.1264] [Reference Citation Analysis]
33 Baracaldo-santamaría D, Barros-arias GM, Hernández-guerrero F, De-la-torre A, Calderon-ospina C. Immune-related adverse events of biological immunotherapies used in COVID-19. Front Pharmacol 2022;13:973246. [DOI: 10.3389/fphar.2022.973246] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
34 Bartoletti M, Azap O, Barac A, Bussini L, Ergonul O, Krause R, Martin-Quiros A, Paño-Pardo JR, Power N, Sibani M, Szabo BG, Tsiodras S, Zollner-Schwetz I, Rodríguez-Baño J. ESCMID COVID-19 guidelines: update on treatment for patients with mild/moderate disease. Clin Microbiol Infect 2022:S1198-743X(22)00429-3. [PMID: 36028088 DOI: 10.1016/j.cmi.2022.08.013] [Reference Citation Analysis]
35 Chew KW, Moser C, Daar ES, Wohl DA, Li JZ, Coombs RW, Ritz J, Giganti M, Javan AC, Li Y, Choudhary MC, Deo R, Malvestutto C, Klekotka P, Price K, Nirula A, Fischer W, Bala V, Ribeiro RM, Perelson AS, Fletcher CV, Eron JJ, Currier JS, Hughes MD, Smith DM; ACTIV-2/A5401 Study Team. Antiviral and clinical activity of bamlanivimab in a randomized trial of non-hospitalized adults with COVID-19. Nat Commun 2022;13:4931. [PMID: 35995785 DOI: 10.1038/s41467-022-32551-2] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
36 Patone M, Snelling AJ, Tibble H, Coupland CA, Sheikh A, Hippisley-cox J. Uptake of Sotrovimab for prevention of severe COVID-19 and its safety in the community in England.. [DOI: 10.1101/2022.08.17.22278893] [Reference Citation Analysis]
37 Biscarini S, Villa S, Genovese C, Tomasello M, Tonizzo A, Fava M, Iannotti N, Bolis M, Mariani B, Valzano AG, Morlacchi LC, Donato F, Castellano G, Cassin R, Carrabba M, Muscatello A, Gori A, Bandera A, Lombardi A. Safety Profile and Outcomes of Early COVID-19 Treatments in Immunocompromised Patients: A Single-Centre Cohort Study. Biomedicines 2022;10:2002. [DOI: 10.3390/biomedicines10082002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
38 Baker JV, Lane HC. The Fast and the Furious: Chasing a Clinical Niche for COVID-19 Convalescent Plasma. Ann Intern Med 2022. [PMID: 35969864 DOI: 10.7326/M22-2329] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
39 Lai C, Wang Y, Chen K, Chen C, Wang C. The Clinical Efficacy and Safety of Anti-Viral Agents for Non-Hospitalized Patients with COVID-19: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials. Viruses 2022;14:1706. [DOI: 10.3390/v14081706] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
40 Birnie E, Biemond JJ, Appelman B, de Bree GJ, Jonges M, Welkers MRA, Wiersinga WJ. Development of Resistance-Associated Mutations After Sotrovimab Administration in High-risk Individuals Infected With the SARS-CoV-2 Omicron Variant. JAMA 2022. [PMID: 35913747 DOI: 10.1001/jama.2022.13854] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
41 Focosi D, Novazzi F, Baj A, Ferrante FD, Boutahar S, Genoni AP, Gasperina DD, Maggi F. Sotrovimab-emergent resistance in SARS-CoV-2 Omicron: A series of three cases. Journal of Clinical Virology Plus 2022;2:100097. [DOI: 10.1016/j.jcvp.2022.100097] [Reference Citation Analysis]
42 Piccicacco N, Zeitler K, Ing A, Montero J, Faughn J, Silbert S, Kim K. Real-world effectiveness of early remdesivir and sotrovimab in the highest-risk COVID-19 outpatients during the Omicron surge. J Antimicrob Chemother 2022:dkac256. [PMID: 35913836 DOI: 10.1093/jac/dkac256] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
43 Maher MC, Soriaga LB, Gupta A, Chen Y, di Iulio J, Ledoux S, Smithey MJ, Cathcart AL, Mckusick K, Sun D, Aldinger M, Alexander E, Purcell L, Ding X, Peppercorn A, Austin D, Mogalian E, Yeh WW, Shapiro AE, Corti D, Virgin HW, Pang PS, Telenti A. Antibody therapy reverses biological signatures of COVID-19 progression. Cell Reports Medicine 2022;3:100721. [DOI: 10.1016/j.xcrm.2022.100721] [Reference Citation Analysis]
44 Martin-Blondel G, Marcelin AG, Soulié C, Kaisaridi S, Lusivika-Nzinga C, Dorival C, Nailler L, Boston A, Melenotte C, Cabié A, Choquet C, Coustillères F, Martellosio JP, Gaube G, Trinh-Duc A, Ronchetti AM, Pourcher V, Chauveau M, Lacombe K, Peiffer-Smadja N, Housset P, Perrot A, Pialoux G, Martin A, Dubee V, Devaux M, Frey J, Cazanave C, Liblau R, Carrat F, Yordanov Y. Sotrovimab to prevent severe COVID-19 in high-risk patients infected with Omicron BA.2. J Infect 2022:S0163-4453(22)00406-6. [PMID: 35803386 DOI: 10.1016/j.jinf.2022.06.033] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
45 Hartman WR. An Executed Plan to Combat COVID-19 in the United States. Advances in Anesthesia 2022. [DOI: 10.1016/j.aan.2022.07.002] [Reference Citation Analysis]
46 Teo SP, Department of Internal Medicine, RIPAS Hospital, Bandar Seri Begawan, BA 1710, Brunei Darussalam.. Sotrovimab for treatment of COVID-19 infections. APT 2022;4:56-59. [DOI: 10.31491/apt.2022.06.087] [Reference Citation Analysis]
47 Bajema KL, Wang XQ, Hynes DM, Rowneki M, Hickok A, Cunningham F, Bohnert A, Boyko EJ, Iwashyna TJ, Maciejewski ML, Viglianti EM, Streja E, Yan L, Aslan M, Huang GD, Ioannou GN. Receipt of anti-SARS-CoV-2 pharmacotherapies among U.S. Veterans with mild to moderate COVID-19, January-February 2022.. [DOI: 10.1101/2022.06.22.22276782] [Reference Citation Analysis]
48 Bajpai P, Singh V, Chandele A, Kumar S. Broadly Neutralizing Antibodies to SARS-CoV-2 Provide Novel Insights Into the Neutralization of Variants and Other Human Coronaviruses. Front Cell Infect Microbiol 2022;12:928279. [DOI: 10.3389/fcimb.2022.928279] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
49 Sang L, Cheng B, Yu Y, Xi Y, Wang Y, Fan B, Li J, Dai J, Gan G, Tong S, Sun B, Qi X, Liang W, He J, Zhong N. The efficacy and safety of IBI314 on delta and omicron variant of SARS-CoV-2: First-in-human evidence. J Infect 2022:S0163-4453(22)00354-1. [PMID: 35691517 DOI: 10.1016/j.jinf.2022.06.004] [Reference Citation Analysis]
50 Hurtado J, Flynn C, Lee JH, Salcedo E, Cottrell CA, Skog PD, Nemazee D, Schief WR, Landais E, Sok D, Briney B. Efficient isolation of rare B cells using next-generation antigen barcoding.. [DOI: 10.1101/2022.06.06.495029] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
51 Sharifan A. COVID- 19 and the Functionality of Antivirals: The Day After Tomorrow. Health Security. [DOI: 10.1089/hs.2022.0073] [Reference Citation Analysis]
52 Zheng B, Green AC, Tazare J, Curtis HJ, Fisher L, Nab L, Schultze A, Mahalingasivam V, Parker EP, Hulme WJ, Bacon SC, Devito NJ, Bates C, Evans D, Inglesby P, Drysdale H, Davy S, Cockburn J, Morton CE, Hickman G, Ward T, Smith RM, Parry J, Hester F, Harper S, Mehrkar A, Eggo RM, Walker AJ, Evans SJ, Douglas IJ, Mackenna B, Goldacre B, Tomlinson LA. Comparative effectiveness of sotrovimab and molnupiravir for prevention of severe COVID-19 outcomes in non-hospitalised patients: an observational cohort study using the OpenSAFELY platform.. [DOI: 10.1101/2022.05.22.22275417] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
53 Vellas C, Tremeaux P, Del Bello A, Latour J, Jeanne N, Ranger N, Danet C, Martin-Blondel G, Delobel P, Kamar N, Izopet J. Resistance mutations in SARS-CoV-2 omicron variant in patients treated with Sotrovimab. Clin Microbiol Infect 2022:S1198-743X(22)00258-0. [PMID: 35595125 DOI: 10.1016/j.cmi.2022.05.002] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
54 Zaqout A, Almaslamani MA, Chemaitelly H, Hashim SA, Ittaman A, Alimam A, Rustom F, Daghfal J, Abukhattab M, Almukdad S, Kaleeckal AH, Latif AN, Butt AA, Bertollini R, Al-khal A, Omrani AS, Abu-raddad LJ. Effectiveness of the neutralizing antibody sotrovimab among high-risk patients with mild to moderate SARS-CoV-2 in Qatar.. [DOI: 10.1101/2022.04.21.22274060] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
55 Solera JT, Árbol BG, Alshahrani A, Bahinskaya I, Marks N, Humar A, Kumar D. Impact of Vaccination and Early Monoclonal Antibody Therapy on COVID-19 Outcomes in Organ Transplant Recipients During the Omicron Wave. Clin Infect Dis 2022:ciac324. [PMID: 35445690 DOI: 10.1093/cid/ciac324] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
56 Fernandes G, Devresse A, Scohy A, De Greef J, Yombi JC, Belkhir L, Darius T, Mourad M, Buemi A, Kabamba B, Goffin E, Kanaan N. Monoclonal Antibody Therapy in Kidney Transplant Recipients With Delta and Omicron Variants of SARS-CoV-2: A Single-Center Case Series. Kidney Medicine 2022. [DOI: 10.1016/j.xkme.2022.100470] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 7.0] [Reference Citation Analysis]
57 Ao G, Li A, Wang Y, Tran C, Qi X. Lack of efficacy for sotrovimab use in patients with COVID-19: A meta-analysis. Journal of Infection 2022. [DOI: 10.1016/j.jinf.2022.04.027] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
58 Mahoney MV, Bhagat H, Christian R, del Rio C, Hohmeier KC, Klepser ME, Pogue JM. Pharmacists as important prescribers of coronavirus disease 2019 (COVID-19) antivirals. ASHE 2022;2:e112. [DOI: 10.1017/ash.2022.248] [Reference Citation Analysis]